Arch Therapeutics Inc (ARTH) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ARTH Annual Balance Sheets →
The table below presents a historical view of Arch Therapeutics Inc's balance sheet, supporting analysis of financial position trends.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2024)
(Mar 31 2024) (Dec 31 2023) (Sep 30 2023) (Jun 30 2023)
Assets
Cash & cash equivalent0.03
Cash & Short-term Investments0.00
Inventories1.32
Prepaid Expense And Other Assets Current0.04
Total Current Assets1.39
Equipment/Property/Plant Net0.00
Other Assets, Noncurrent0.00
Total Assets1.40
Liabilities
Accounts Payable, Current AC2.92
Interest Payable, Current IN1.25
Convertible Notes Payable, Current NO6.70
Other Liabilities, Current3.09
Total Current Liabilities13.96
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Shareholder Advances Current-
Total Liabilities13.96
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock60.03
Retained Earnings / Accumulated Deficit-72.59
Other Equity0.00
Common Stockholder's Equity-12.56
Total Stockholder's Equity-12.56
Liabilities & Stockholder's Equity1.40
4 historic quarters locked

Sign in to unlock the full Arch Therapeutics Inc balance sheet history.

About Arch Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q (Period: 20240630)
  • Filed with the SEC: August 19, 2024
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001493152-24-033091

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.